Trans-6-cyano-4-cyclohexylthio-2,2-dimethyl-3-hydroxychroman

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: Trans-6-cyano-4-cyclohexylthio-2,2-dimethyl-3-hydroxychroman
• 英文别名: (3R,4R)-4-cyclohexylsulfanyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrile
• 化学式: C₁₈H₂₃NO₂S
• 分子量: 317.452
• InChiKey: OLAYEQGZSMAGOG-SJORKVTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  78.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Trans-6-cyano-4-cyclohexylthio-2,2-dimethyl-3-hydroxychroman 、 间氯过氧苯甲酸 生成 Trans-6-cyano-4-cyclohexylsulfonyl-2,2-dimethyl-3-hydroxychroman
  参考文献：
  名称：

  GARCIA, GEORGES;DI, MALTA ALAIN;SOUBRIE, PHILIPPE

  摘要：

  DOI：
• 作为产物：
  描述：

  环己硫醇 、 3,4-epoxy-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile 在 苄基三甲基氢氧化铵 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 生成 Trans-6-cyano-4-cyclohexylthio-2,2-dimethyl-3-hydroxychroman
  参考文献：
  名称：

  Novel chroman derivatives active on the central nervous system, their

  摘要：

  式为##STR1##的化合物中：Z代表卤素或氰基，乙酰基，三氟乙酰基，硝基，C.sub.1 -C.sub.4烷基硫基，羧基，膦酸基，二烷氧基膦酰基或烷氧羰基，烷硫基和烷氧基含有1至3个碳原子；R.sub.1代表羟基，R.sub.2代表氢，或R.sub.1和R.sub.2一起形成它们所携带的碳原子之间的额外键；R.sub.3代表NH--X--R.sub.4基团，其中X代表直接键或一个SO.sub.2基团，R.sub.4代表未取代或经卤素、硝基、C.sub.1 -C.sub.4基团、三氟甲基基团、氨基、--N(Alk).sub.2基团、--COOAlk基团或OAlk基团取代的苯基团，其中Alk代表C.sub.1 -C.sub.4烷基；一个--S--R.sub.5基团，其中R.sub.5代表C.sub.1 -C.sub.4烷基、C.sub.3 -C.sub.7环烷基或未取代或经卤素、硝基、C.sub.1 -C.sub.4基团、三氟甲基基团、氨基、--N(Alk).sub.2基团、--COOAlk基团或AlOk基团取代的苯基，其中Alk代表C.sub.1 -C.sub.4烷基；或R.sub.5代表一个--AlkN(Alk).sub.2基团，其中Alk如上定义；或一个SO.sub.2 R.sub.5基团，其中R.sub.5如上定义，以及当取代基R.sub.3包括氨基时，化合物的配制药学可接受酸盐。

  公开号：

  US05082858A1

文献信息

• Chroman derivative active on the central nervous system, their method of
  申请人：Sanofi

  公开号：US05151442A1

  公开（公告）日：1992-09-29

  Compounds of the formula ##STR1## in which: Z represents a halogen or a cyano, acetyl, trifluoroacetyl, nitro, C.sub.1 -C.sub.4 alkylthio, carboxyl, phosphono, dialkoxyphosphonyl or alkoxycarbonyl group, the alkylthio and alkoxy groups containing from 1 to 3 carbon atoms; R.sub.1 denotes a hydroxyl group and R.sub.2 represents hydrogen, or R.sub.1 and R.sub.2 taken together form an additional bond between the carbon atoms by which they are carried; and R.sub.3 represents a group NH--X--R.sub.4, in which X denotes a direct bond or an SO.sub.2 group and R.sub.4 represents a phenyl group which is unsubstituted or monosubstituted or disubstituted by a halogen, a nitro group, a C.sub.1 -C.sub.4 group, a trifluoromethyl group, an amino group, a group --N(Alk).sub.2, a group --COOAlk or a group OAlk, Alk denoting a C.sub.1 -C.sub.4 Alkyl group; a group --S--R.sub.5, in which R.sub.5 represents a C.sub.1 -C.sub.4 alkyl group, a C.sub.3 -C.sub.7 cycloalkyl or a phenyl group which is unsubstituted or monosubstituted or disubstituted by a halogen, a nitro group, a C.sub.1 -C.sub.4 alkyl group, a trifluoromethyl group, an amino group, a group --N(Alk).sub.2, a group --COOAlk or a group OAlk, Alk denoting a C.sub.1 -C.sub.4 alkyl gropu; or R.sub.5 denotes a group --AlkN(Alk).sub.2 in which Alk is as defined above; or a group SO.sub.2 R.sub.5, in which R.sub.5 is as defined above, and the salts which the compounds of formula (I) are capable of producing with pharmaceutically acceptable acids when the substituent R.sub.3 comprises an amino group.

  公式为##STR1##的化合物中：Z代表卤素或氰基，乙酰基，三氟乙酰基，硝基，C.sub.1-C.sub.4烷基硫醚，羧基，磷酸基，二烷氧基膦酰基或烷氧羰基基团，烷氧和烷硫基团含有1至3个碳原子；R.sub.1表示一个羟基，R.sub.2代表氢，或R.sub.1和R.sub.2在它们所携带的碳原子之间形成一个额外的键；R.sub.3表示一个NH--X--R.sub.4基团，其中X表示直接键或SO.sub.2基团，R.sub.4表示未取代或单取代或双取代的苯基，其通过卤素，硝基，C.sub.1-C.sub.4基团，三氟甲基基团，氨基，--N（Alk）.sub.2基团，--COOAlk基团或OAlk基团进行取代，Alk表示C.sub.1-C.sub.4烷基；一个--S--R.sub.5基团，其中R.sub.5表示C.sub.1-C.sub.4烷基，C.sub.3-C.sub.7环烷基或未取代或单取代或双取代的苯基，其通过卤素，硝基，C.sub.1-C.sub.4烷基，三氟甲基基团，氨基，--N（Alk）.sub.2基团，--COOAlk基团或OAlk基团进行取代，Alk表示C.sub.1-C.sub.4烷基；或R.sub.5表示一个--AlkN（Alk）.sub.2基团，其中Alk如上所定义；或一个SO.sub.2R.sub.5基团，其中R.sub.5如上所定义，并且当取代基R.sub.3包括氨基时，化合物（I）的药学可接受酸盐。
• GARCIA, GEORGES;DI, MALTA ALAIN;SOUBRIE, PHILIPPE
  作者：GARCIA, GEORGES、DI, MALTA ALAIN、SOUBRIE, PHILIPPE

  DOI：——

  日期：——
• US5082858A
  申请人：——

  公开号：US5082858A

  公开（公告）日：1992-01-21
• US5151442A
  申请人：——

  公开号：US5151442A

  公开（公告）日：1992-09-29
• Novel chroman derivatives active on the central nervous system, their
  申请人：Sanofi

  公开号：US05082858A1

  公开（公告）日：1992-01-21

  Compounds of the formula ##STR1## in which: Z represents a halogen or a cyano, acetyl, trifluoroacetyl, nitro, C.sub.1 -C.sub.4 alkylthio, carboxyl, phosphono, dialkoxyphosphonyl or alkoxycarbonyl group, the alkylthio and alkoxy groups containing from 1 to 3 carbon atoms; R.sub.1 denotes a hydroxyl group and R.sub.2 represents hydrogen, or R.sub.1 and R.sub.2 taken together form an additional bond between the carbon atoms by which they are carried; and R.sub.3 represents a group NH--X--R.sub.4, in which X denotes a direct bond or an SO.sub.2 group and R.sub.4 represents a phenyl group which is unsubstituted or monosubstituted or disubstituted by a halogen, a nitro group, a C.sub.1 -C.sub.4 group, a trifluoromethyl group, an amino group, a group --N(Alk).sub.2, a group --COOAlk or a group OAlk, Alk denoting a C.sub.1 -C.sub.4 alkyl group; a group --S--R.sub.5, in which R.sub.5 represents a C.sub.1 -C.sub.4 alkyl group, a C.sub.3 -C.sub.7 cycloalkyl or a phenyl group which is unsubstituted or monosubstituted or disubstituted by a halogen, a nitro group, a C.sub.1 -C.sub.4 group, a trifluoromethyl group, an amino group, a group --N(Alk).sub.2, a group --COOAlk or a group AlOk, Alk denoting a C.sub.1 -C.sub.4 alkyl group; or R.sub.5 denotes a group --AlkN(Alk).sub.2 in which Alk is as defined above; or a group SO.sub.2 R.sub.5, in which R.sub.5 is as defined above, and the salts which the compounds of formula (I) are capable of producing with pharmaceutically acceptable acids when the substituent R.sub.3 comprises an amino group.

  式为##STR1##的化合物中：Z代表卤素或氰基，乙酰基，三氟乙酰基，硝基，C.sub.1 -C.sub.4烷基硫基，羧基，膦酸基，二烷氧基膦酰基或烷氧羰基，烷硫基和烷氧基含有1至3个碳原子；R.sub.1代表羟基，R.sub.2代表氢，或R.sub.1和R.sub.2一起形成它们所携带的碳原子之间的额外键；R.sub.3代表NH--X--R.sub.4基团，其中X代表直接键或一个SO.sub.2基团，R.sub.4代表未取代或经卤素、硝基、C.sub.1 -C.sub.4基团、三氟甲基基团、氨基、--N(Alk).sub.2基团、--COOAlk基团或OAlk基团取代的苯基团，其中Alk代表C.sub.1 -C.sub.4烷基；一个--S--R.sub.5基团，其中R.sub.5代表C.sub.1 -C.sub.4烷基、C.sub.3 -C.sub.7环烷基或未取代或经卤素、硝基、C.sub.1 -C.sub.4基团、三氟甲基基团、氨基、--N(Alk).sub.2基团、--COOAlk基团或AlOk基团取代的苯基，其中Alk代表C.sub.1 -C.sub.4烷基；或R.sub.5代表一个--AlkN(Alk).sub.2基团，其中Alk如上定义；或一个SO.sub.2 R.sub.5基团，其中R.sub.5如上定义，以及当取代基R.sub.3包括氨基时，化合物的配制药学可接受酸盐。